AR126251A1 - Inhibidores de cdk2 - Google Patents

Inhibidores de cdk2

Info

Publication number
AR126251A1
AR126251A1 ARP220101677A ARP220101677A AR126251A1 AR 126251 A1 AR126251 A1 AR 126251A1 AR P220101677 A ARP220101677 A AR P220101677A AR P220101677 A ARP220101677 A AR P220101677A AR 126251 A1 AR126251 A1 AR 126251A1
Authority
AR
Argentina
Prior art keywords
pharmaceutically acceptable
cdk2 inhibitors
acceptable salt
compound
useful
Prior art date
Application number
ARP220101677A
Other languages
English (en)
Inventor
Douglas Wilson
Jr Neil Bifulco
Natasja Brooijmans
Joseph L Kim
Emanuele Perola
Philip D Ramsden
Richard Vargas
Steven Mark Wenglowsky
Original Assignee
Blueprint Medicines Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blueprint Medicines Corp filed Critical Blueprint Medicines Corp
Publication of AR126251A1 publication Critical patent/AR126251A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Abstract

La presente descripción proporciona un compuesto representado por la fórmula estructural (1), o una sal farmacéuticamente aceptable de este útiles para tratar el cáncer. Una composición farmacéutica que comprende un portador farmacéuticamente aceptable y un compuesto de cualquiera de las reivindicaciones 1 - 51, o una sal farmacéuticamente aceptable de este.
ARP220101677A 2021-06-28 2022-06-27 Inhibidores de cdk2 AR126251A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163215901P 2021-06-28 2021-06-28

Publications (1)

Publication Number Publication Date
AR126251A1 true AR126251A1 (es) 2023-10-04

Family

ID=82655170

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220101677A AR126251A1 (es) 2021-06-28 2022-06-27 Inhibidores de cdk2

Country Status (12)

Country Link
US (1) US11932648B2 (es)
KR (1) KR20240046167A (es)
CN (1) CN117897384A (es)
AR (1) AR126251A1 (es)
AU (1) AU2022301047A1 (es)
CA (1) CA3223223A1 (es)
CO (1) CO2024000237A2 (es)
DO (1) DOP2023000280A (es)
IL (1) IL309118A (es)
TW (1) TW202317574A (es)
UY (1) UY39832A (es)
WO (1) WO2023278326A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY39832A (es) 2021-06-28 2023-01-31 Blueprint Medicines Corp Inhibidores de cdk2

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1518543A (zh) 2000-08-31 2004-08-04 �Ʒ� 吡唑衍生物和它们作为蛋白激酶抑制剂的用途
AU2001292670A1 (en) 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
BR0116411A (pt) 2000-12-21 2003-11-11 Vertex Pharma Compostos de pirazol úteis como inibidores de proteìna cinase
AU2005205118B2 (en) 2004-01-09 2009-02-26 Novartis Ag Phenyl-[4-(3-phenyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amine derivatives as IGF-IR inhibitors
US8362031B2 (en) 2004-08-20 2013-01-29 University Of Kansas Lonidamine analogues and treatment of polycystic kidney disease
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
EP1926734A1 (en) 2005-08-22 2008-06-04 Amgen Inc. Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators
DE102008063992A1 (de) 2008-12-19 2010-09-02 Lerner, Zinoviy, Dipl.-Ing. Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
KR20110049217A (ko) 2009-11-04 2011-05-12 다우어드밴스드디스플레이머티리얼 유한회사 신규한 유기 발광 화합물 및 이를 채용하고 있는 유기 전계 발광 소자
KR20120063283A (ko) 2010-12-07 2012-06-15 제일약품주식회사 신규한 피라졸로 피리딘 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 약학적 조성물
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
PT2994465T (pt) 2013-05-10 2018-10-25 Karus Therapeutics Ltd Novos inibidores de histona desacetilase
KR20160036053A (ko) 2013-07-31 2016-04-01 메르크 파텐트 게엠베하 Btk 저해제로서 피리딘, 피리미딘, 및 피라진, 및 이들의 용도
WO2016057322A1 (en) 2014-10-08 2016-04-14 Salk Institute For Biological Studies Ppar agonists and methods of use thereof
MX2017015521A (es) 2015-06-04 2018-11-09 Aurigene Discovery Tech Ltd Derivados de heterociclilos sustituidos como inhibidores de cdk.
US11459308B2 (en) 2016-12-05 2022-10-04 Microbiotix, Inc. Broad spectrum inhibitors of filoviruses
EP3768680A1 (en) 2018-03-21 2021-01-27 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors and methods of use thereof
GB201808093D0 (en) 2018-05-18 2018-07-04 Enterprise Therapeutics Ltd Compounds
TWI740288B (zh) 2018-11-27 2021-09-21 大陸商江蘇豪森藥業集團有限公司 含氮雜芳類衍生物調節劑、其製備方法和應用
TWI741423B (zh) 2018-11-30 2021-10-01 大陸商江蘇豪森藥業集團有限公司 雜芳類衍生物調節劑、其製備方法和應用
JP7094456B2 (ja) 2019-01-31 2022-07-01 ファイザー・インク Ｃｄｋ２阻害剤
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
WO2020264420A1 (en) 2019-06-28 2020-12-30 Gb002, Inc. Heterocyclic kinase inhibitors and products and uses thereof
US11851426B2 (en) 2019-10-11 2023-12-26 Incyte Corporation Bicyclic amines as CDK2 inhibitors
WO2022061155A1 (en) 2020-09-17 2022-03-24 The Translational Genomics Research Institute Imidazopyridazine and imidazopyrazine compounds as inhibitors of cdk7
WO2022245776A1 (en) 2021-05-20 2022-11-24 Saint John's Cancer Institute Anti-cdk inhibitors for cancer treatment
IL309013A (en) 2021-06-16 2024-01-01 Blueprint Medicines Corp Converted pyrimidinylpyrazoles as CDK2 inhibitors
US20230002376A1 (en) 2021-06-21 2023-01-05 Incyte Corporation Bicyclic pyrazolyl amines as cdk2 inhibitors
UY39832A (es) 2021-06-28 2023-01-31 Blueprint Medicines Corp Inhibidores de cdk2
WO2023092088A1 (en) 2021-11-19 2023-05-25 Blueprint Medicines Corporation Cdk2 inhibitors and methods of making and using same

Also Published As

Publication number Publication date
AU2022301047A1 (en) 2024-01-04
TW202317574A (zh) 2023-05-01
CO2024000237A2 (es) 2024-02-05
US20230159535A1 (en) 2023-05-25
KR20240046167A (ko) 2024-04-08
US20230322791A1 (en) 2023-10-12
IL309118A (en) 2024-02-01
UY39832A (es) 2023-01-31
US11932648B2 (en) 2024-03-19
CA3223223A1 (en) 2023-01-05
CN117897384A (zh) 2024-04-16
WO2023278326A1 (en) 2023-01-05
DOP2023000280A (es) 2024-03-28

Similar Documents

Publication Publication Date Title
ECSP22057865A (es) Inhibidores de formas mutantes de egfr
CO2022012975A2 (es) Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead
BR112018070677A2 (pt) inibidores de mcl-1 macrocíclicos para o tratamento de câncer
AR106237A2 (es) Inhibidores heterocíclicos de la aspartil proteasa, sus sales farmacéuticamente aceptables
BR112021020637A2 (pt) Derivados de tetra-hidro-1h-ciclopenta[cd]indeno como inibidores de fator -2(alfa) induzível por hipóxia
AR057874A1 (es) Aminopirimidinas utiles como inhibidores de quinasa
AR107864A1 (es) ÁCIDO 7a,11b-DIHIDROXI-6a-ETIL-5b-COLAN-24-OICO Y COMPOSICIONES FARMACÉUTICAS
CL2004000076A1 (es) Compuestos derivados de indol, inhibidores de polimerasa, sales; composicion farmaceutica que los comprende; procedimiento de preparacion de dichos compuestos; compuestos intermediarios; y uso del compuesto para tratar una infeccion causada por el vi
CL2020001752A1 (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa.
UY39027A (es) Uso de favipiravir en el tratamiento de la infección por coronavirus
CO2021005532A2 (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
CO2021016504A2 (es) Inhibidores de cdk
MX2019006843A (es) Inhibidor de cdk4/6.
CR20190236A (es) Compuestos terapéuticos y métodos para utilizarlos
UY37941A (es) Derivados de bencimidazol y sus usos
CO2021014210A2 (es) Compuestos de pirrol
AR122351A1 (es) Derivados de metilquinazolinona como inhibidores de braf
AR124449A1 (es) Inhibidores de sos1 y usos de los mismos
AR126251A1 (es) Inhibidores de cdk2
CO2024000221A2 (es) Pirimidinil-pirazoles sustituidos como inhibidores de cdk2
CL2021003202A1 (es) Compuestos de pirrolidina
AR057403A1 (es) 4- anilino-3-quinolincarbonitrilos para el tratamiento del cancer
CO2021017202A2 (es) Compuestos tricíclicos
AR105400A1 (es) Inhibidores de jak1
UY39662A (es) Inhibidores de egfr